Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,609 Shares

President and CEO of Neurocrine Biosciences Inc. (NBIX, Financial) Kevin Charles Gorman sells 15,609 shares of NBIX on 03/01/2010 at an average price of $2.53 a share.

Neurocrine Biosciences Inc. has a market cap of $103.1 million; its shares were traded at around $2.63 with and P/S ratio of 34.9. Neurocrine Biosciences Inc. had an annual average earning growth of 21.7% over the past 5 years.

NBIX is in the portfolios of Stanley Druckenmiller of Duquesne Capital Management, LLC, Jim Simons of Renaissance Technologies LLC.

CEO Recent Trades:

  • Sell:: President and CEO Kevin Charles Gorman sold 9,445 shares of NBIX stock on 01/12/2010 at the average price of 2.52, the price of the stock has increased by 4.37% since.



CFO Recent Trades:

  • Sell:: VP and CFO Timothy P Coughlin sold 8,697 shares of NBIX stock on 01/12/2010 at the average price of 2.52, the price of the stock has increased by 4.37% since.



Directors and Officers Recent Trades:

  • Buy:: Director W Thomas Mitchell bought 900 shares of NBIX stock on 11/05/2009 at the average price of 2.17, the price of the stock has increased by 21.2% since.

  • Sell:: EVP and General Counsel Jensen Margaret E Valeur sold 8,697 shares of NBIX stock on 01/12/2010 at the average price of 2.52, the price of the stock has increased by 4.37% since.

  • Sell:: Sr. VP & Chief Medical Officer Christopher Flint Obrien sold 1,503 shares of NBIX stock on 01/04/2010 at the average price of 2.65, the price of the stock has decreased by 0.75% since.

  • Sell:: Sr Vice President, Development Haig P. Bozigian sold 751 shares of NBIX stock on 01/04/2010 at the average price of 2.64, the price of the stock has decreased by 0.38% since.

  • Sell:: Vice President, Research Dimitri E. Grigoriadis sold 1,503 shares of NBIX stock on 01/04/2010 at the average price of 2.67, the price of the stock has decreased by 1.5% since.